| 发明名称 | Post-translationally modified neurotrophin antibodies | ||
| 摘要 | The present invention describes that neurotrophins undergo post-translational modifications, and that these post-translational modifications mediate the pro-apoptotic and/or pro-neurite activity of neurotrophins. These post-translational modifications notably include nitration and the formation of conformationally-different dimers, as well as of abnormal oligomers, such as tetramers and octamers. The invention further relates to compounds that compete with such modified neurotrophins, as well as to compounds that bind to these modified neurotrophins. The invention thus provides useful agents for the treatment of the conditions or diseases involving chronic pain and/or neuron loss. | ||
| 申请公布号 | US9328163(B2) | 申请公布日期 | 2016.05.03 |
| 申请号 | US201314037973 | 申请日期 | 2013.09.26 |
| 申请人 | INSTITUT PASTEUR;INSTITUTO DE INVESTIGACIONES BIOLOGICAS CLEMENTE ESTABLE;FACULTAD DE MEDICINA, UNIVERSIDAD DE LA REPUBLICA;CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | 发明人 | Barbeito Luis;Pehar Mariana;Cassina Patricia;Alzari Pedro M. |
| 分类号 | C07K16/22;A61K39/395;C07K14/475;C07K14/48;A61K38/00 | 主分类号 | C07K16/22 |
| 代理机构 | Law Office of Salvatore Arrigo and Scott Lee, LLP | 代理人 | Law Office of Salvatore Arrigo and Scott Lee, LLP |
| 主权项 | 1. An isolated hNGF-binding monoclonal antibody that binds specifically to hNGF (SEQ ID NO:2) when it has been nitrated on Trp21, Tyr52, Trp76, Tyr79, or Trp99, but does not bind to hNGF (SEQ ID NO:2) when it has not been nitrated. | ||
| 地址 | Paris FR | ||